BillionToOne (BLLN) Q1 2026 earnings review
Hyper-Growth Meets Expanding Profitability
BillionToOne delivered a flawless Q1 2026, breaking the traditional biotech trade-off between scale and margins. Revenue surged 84% to $108.4 million, fundamentally driven by expanding Average Selling Prices (ASP) and a nearly 5x explosion in Oncology volumes. More importantly, gross margins expanded 900 basis points YoY to 73%, completely erasing earlier concerns that the lower-margin oncology segment would drag down profitability. Operating income flipped from a $2.3M loss a year ago to a $17.8M profit (16% margin). Management raised FY26 guidance, though the implied deceleration in the back half of the year suggests the easiest comps are now in the rearview mirror.
🐂 Bull Case
Overall ASP expanded 28% YoY to $571, allowing gross margins to hit 73%. The combination of higher prices and a 44% increase in delivered tests creates a compounding effect on the bottom line.
Oncology revenue grew 392% YoY to $10.7M. As this segment becomes a larger piece of the pie, its absolute dollar contribution to gross profit is accelerating rapidly.
🐻 Bear Case
While Q1 revenue grew 84%, the raised FY26 guidance of $450-$465M implies full-year growth of roughly 50%. This mathematically forces severe deceleration in YoY growth rates in H2 26 due to tougher comps.
Management expects to operate the business to generate profitability 'approaching current levels' for the rest of the year. This specific phrasing suggests Q1's 16% operating margin might be a near-term ceiling as they reinvest in the business.
⚖️ Verdict: 🟢🟢
Extremely Bullish. Achieving 84% revenue growth alongside a massive positive swing in GAAP operating income demonstrates that the core technology moat translates directly into superior unit economics.
Key Themes
ASP Expansion Shatters Gross Margin Headwinds
In late 2025, management warned of a 'negative mix shift' because the hyper-growth oncology segment carried lower gross margins than prenatal. Q1 2026 data completely invalidated this concern. Driven by better payer coverage and Medicaid code adoptions, the blended Average Selling Price (ASP) jumped 28% YoY to $571. Consequently, Gross Margin expanded from 64% in 25Q1 to 73% in 26Q1, proving they can outgrow the mix-shift headwind via raw pricing power.
Oncology Segment Hyper-Growth Continues
Oncology clinical testing revenue hit $10.7 million, nearly quintupling (+392%) from $2.2 million a year ago. While Prenatal remains the cash cow ($96.5 million, +72%), Oncology is quickly transitioning from a speculative pipeline project to a primary revenue pillar.
Product Innovation: Unity Confirm Launch
The company launched Unity Confirm, utilizing its Fetal Cell Capture technology. By isolating intact circulating fetal cells from a simple blood draw to verify high-risk screening results, they eliminate the need for dangerous invasive procedures like amniocentesis. This significantly expands their addressable market within high-risk pregnancies.
Implied Growth Deceleration Masks Q1 Beat
Q1 delivered a staggering 84% YoY revenue increase. However, full-year guidance was raised to $450-$465 million, which represents 48% to 52% growth over 2025. By mathematically subtracting Q1's $108.4 million, the company must average roughly $117 million per quarter for the rest of the year. This implies that while absolute dollar growth is fine, the YoY percentage growth will crater in H2 26 due to the tougher comps created by the late 2025 volume surge.
Operating Leverage May Have Formed a Ceiling
Operating Income was $17.8 million in Q1 (16.4% margin). In the guidance, management explicitly stated they expect to operate so they 'continue to generate profitability approaching current levels, even with significant continued investments.' The word 'approaching' is a coded warning: margins are unlikely to expand further this year, and may slightly compress, as they ramp up spend on R&D, sales force expansion, and Epic EMR integrations.
Reimbursement Dependency and Medicare Timelines
A massive piece of the company's future valuation rests on securing Medicare MolDX coverage for its Northstar Response oncology test, which management previously slated for late 2026. Any regulatory delays in this macro-reimbursement environment could severely stall the 2:1 recurring revenue ratio they rely on for long-term oncology growth.
Other KPIs
Accelerating. Generating strong positive free cash flow proves the company is now fully self-sustaining. With over $537 million in cash and equivalents on the balance sheet following the late-2025 IPO, dilution risk is practically zero.
Accelerating. Up 44% YoY compared to 131,000 in Q1 2025. Volume growth is healthy across both primary business lines, ensuring revenue isn't entirely dependent on favorable pricing actions.
Accelerating, but at a controlled pace. OPEX grew 52% YoY, which is significantly slower than the 84% revenue growth, resulting in massive positive operating leverage.
Guidance
Decelerating mathematically, but an absolute raise. Increased from the prior range of $430M-$445M. The midpoint implies 50% YoY growth. Because Q1 grew at 84%, the rest of the year implies heavy deceleration in growth rates (likely dropping toward 30-40% YoY in Q4) as they lap the massive Q3/Q4 2025 quarters.
Key Questions
ASP Ceiling
Overall ASP grew to $571 this quarter. How much of this was a one-time catch-up in Medicaid coding versus a structural, repeatable baseline? Where does ASP plateau?
Epic Integration Update
In Q3 2025, you announced a major Epic EMR integration expected to take 9 months to go live. Are those implementations complete, and is that volume factored into the H2 2026 guidance raise?
Margin Philosophy
Guidance points to profitability 'approaching' Q1 levels for the rest of the year. Are you intentionally capping operating margins in the mid-teens to fund specific R&D initiatives, like the Tumor-naive MRD pipeline?
Oncology Sales Force Productivity
Oncology grew 392% YoY. Are you still hiring 4-7 oncology reps per quarter, and are the newer cohorts reaching productivity faster than historical averages?